Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy

Christelle Zaghrini, Barbara Seitz-Polski, Joana Justino, Guillaume Dolla, Christine Payré, Noémie Jourde-Chiche, Anne-Els Van de Logt, Caroline Booth, Emma Rigby, Jennie Lonnbro-Widgren, Jenny Nystrom, Christophe Mariat, Zhao Cui, Jack F M Wetzels, GianMarco Ghiggeri, Laurence H Beck, Pierre Ronco, Hanna Debiec, Gérard Lambeau

Research output: Contribution to journalArticlepeer-review


Autoantibodies against phospholipase A2 receptor 1 (PLA2R1) and thrombospondin type 1 domain-containing 7A (THSD7A) are emerging as biomarkers to classify membranous nephropathy (MN) and to predict outcome or response to treatment. Anti-THSD7A autoantibodies are detected by Western blot and indirect immunofluorescence test (IIFT). Here, we developed a sensitive enzyme-linked immunosorbent assay (ELISA) optimized for quantitative detection of anti-THSD7A autoantibodies. Among 1012 biopsy-proven MN patients from 6 cohorts, 28 THSD7A-positive patients were identified by ELISA, indicating a prevalence of 2.8%. By screening additional patients, mostly referred because of PLA2R1-unrelated MN, we identified 21 more cases, establishing a cohort of 49 THSD7A-positive patients. Twenty-eight patients (57%) were male, and male patients were older than female patients (67 versus 49 years). Eight patients had a history of malignancy, but only 3 were diagnosed with malignancy within 2 years of MN diagnosis. We compared the results of ELISA, IIFT, Western blot, and biopsy staining, and found a significant correlation between ELISA and IIFT titers. Anti-THSD7A autoantibodies were predominantly IgG4 in all patients. Eight patients were double positive for THSD7A and PLA2R1. Levels of anti-THSD7A autoantibodies correlated with disease activity and with response to treatment. Patients with high titer at baseline had poor clinical outcome. In a subgroup of patients with serial titers, persistently elevated anti-THSD7A autoantibodies were observed in patients who did not respond to treatment or did not achieve remission. We conclude that the novel anti-THSD7A ELISA can be used to identify patients with THSD7A-associated MN and to monitor autoantibody titers during treatment.

Original languageEnglish
Pages (from-to)666-679
Number of pages14
JournalKidney International
Issue number3
Publication statusPublished - Mar 2019


Dive into the research topics of 'Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy'. Together they form a unique fingerprint.

Cite this